We are live on ! Find out more
SURF

Surface Oncology, Inc. Common Stock

Delisted

SURF was delisted on the 7th of September, 2023.

35 hedge funds and large institutions have $20.9M invested in Surface Oncology, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

26% less funds holding

Funds holding: 4735 (-12)

53% less capital invested

Capital invested by funds: $44.4M → $20.9M (-$23.5M)

53% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 17

80% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 15

Holders
35
Holders Change
-12
Holders Change %
-25.53%
% of All Funds
0.77%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
3
Increased
8
Reduced
17
Closed
15
Calls
Puts
Net Calls
Net Calls Change

SURF Hedge Fund Activity: Q3 2019 in Review

35 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q3 2019, worth a combined $20.9M — down 53% from $44.4M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of SURF and 3 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 8 added.

The largest buyer was RBF Capital, opening a new position worth an estimated $221K. The largest seller was EcoR1 Capital, cutting an estimated $1.67M.

  • 35 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q3 2019, down from 47 in Q2 2019.
  • Funds reported $20.9M of Surface Oncology, Inc. Common Stock stock for Q3 2019, down 53% quarter-over-quarter.
  • 3 funds opened new Surface Oncology, Inc. Common Stock positions in Q3 2019 and 15 closed out, a net change of -12 holders.
  • The largest Surface Oncology, Inc. Common Stock buyer in Q3 2019 was RBF Capital, an estimated $221K added.
  • The largest Surface Oncology, Inc. Common Stock seller in Q3 2019 was EcoR1 Capital, an estimated $1.67M sold.

Based on aggregated 13F filings for Q3 2019.